eXoZymes (NASDAQ:EXOZ) versus Janux Therapeutics (NASDAQ:JANX) Head-To-Head Comparison

eXoZymes (NASDAQ:EXOZ) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Valuation & Earnings

This table compares eXoZymes and Janux Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70,000.00	1,201.74	-$9.16 million	($1.14)	-8.70
Janux Therapeutics	$10.00 million	88.54	-$113.62 million	($1.84)	-7.89

eXoZymes has higher earnings, but lower revenue than Janux Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

eXoZymes has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for eXoZymes and Janux Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1	0	0	0	1.00
Janux Therapeutics	2	3	9	1	2.60

Janux Therapeutics has a consensus price target of $45.85, indicating a potential upside of 215.74%. Given Janux Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than eXoZymes.

Institutional and Insider Ownership

75.4% of Janux Therapeutics shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares eXoZymes and Janux Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Janux Therapeutics	N/A	-12.93%	-12.23%

Summary

Janux Therapeutics beats eXoZymes on 9 of the 14 factors compared between the two stocks.

About eXoZymes

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.